All recalls
Every recall from CPSC, FDA, USDA and NHTSA, newest first. Each one links to the agency's official notice. Looking for one product? Check a product.
2,237 recalls · page 11 of 45
-
Class IIofficial
GE Healthcare Ireland Limited recalls GE Healthcare Omnipaque (iohexol) InjectionPresence of particulate matter
-
Class IIofficial
GE Healthcare Ireland Limited recalls GE Healthcare Omnipaque (iohexol) InjectionPresence of particulate matter
-
Class IIofficial
The Harvard Drug Group LLC recalls Memantine Hydrochloride Extended-ReleaseFailed Dissolution Specifications
-
Class Iofficial
Buy-Herbal recalls Kian Pee Wan CapsulesMarketed Without an Approved NDA/ANDA: Product contains undeclared drug ingredients dexamethasone and cyproheptadine.
-
Class IIofficial
Fagron Compounding Services recalls norepinephrine BitartrateLack of Assurance of Sterility; blue Break-Off-Part could detach from the administration port
-
Class IIofficial
Fagron Compounding Services recalls norepinephrine BitartrateLack of Assurance of Sterility; blue Break-Off-Part could detach from the administration port
-
Class IIofficial
Fagron Compounding Services recalls Vancomycin HCILack of Assurance of Sterility; blue Break-Off-Part could detach from the administration port
-
Class IIofficial
Fagron Compounding Services recalls Vancomycin HCILack of Assurance of Sterility; blue Break-Off-Part could detach from the administration port
-
Class IIofficial
Fagron Compounding Services recalls Vancomycin HCLLack of Assurance of Sterility; blue Break-Off-Part could detach from the administration port
-
Class IIofficial
Xiamen Kang Zhongyuan Biotechnology Co., Ltd. recalls exchange selectThis recall is being initiated following FDA's recommendation based on certain observations noted during an August 15, 2025, inspection of the manufacturing facility that may bear on product quality.
-
Class IIofficial
Xiamen Kang Zhongyuan Biotechnology Co., Ltd. recalls exchange selectThis recall is being initiated following FDA's recommendation based on certain observations noted during an August 15, 2025, inspection of the manufacturing facility that may bear on product quality.
-
Class IIofficial
Xiamen Kang Zhongyuan Biotechnology Co., Ltd. recalls caring millThis recall is being initiated following FDA's recommendation based on certain observations noted during an August 15, 2025, inspection of the manufacturing facility that may bear on product quality.
-
Class IIofficial
Xiamen Kang Zhongyuan Biotechnology Co., Ltd. recalls Discount Drug Mart Food MarketThis recall is being initiated following FDA's recommendation based on certain observations noted during an August 15, 2025, inspection of the manufacturing facility that may bear on product quality.
-
Class IIofficial
Xiamen Kang Zhongyuan Biotechnology Co., Ltd. recalls Discount Drug Mart Food MarketThis recall is being initiated following FDA's recommendation based on certain observations noted during an August 15, 2025, inspection of the manufacturing facility that may bear on product quality.
-
Class IIofficial
Xiamen Kang Zhongyuan Biotechnology Co., Ltd. recalls MGC HealthThis recall is being initiated following FDA's recommendation based on certain observations noted during an August 15, 2025, inspection of the manufacturing facility that may bear on product quality.
-
Class IIofficial
Xiamen Kang Zhongyuan Biotechnology Co., Ltd. recalls MGC HealthThis recall is being initiated following FDA's recommendation based on certain observations noted during an August 15, 2025, inspection of the manufacturing facility that may bear on product quality.
-
Class IIofficial
Xiamen Kang Zhongyuan Biotechnology Co., Ltd. recalls MGC HealthThis recall is being initiated following FDA's recommendation based on certain observations noted during an August 15, 2025, inspection of the manufacturing facility that may bear on product quality.
-
Class IIofficial
Xiamen Kang Zhongyuan Biotechnology Co., Ltd. recalls QC Quality ChoiceThis recall is being initiated following FDA's recommendation based on certain observations noted during an August 15, 2025, inspection of the manufacturing facility that may bear on product quality.
-
Class IIofficial
Xiamen Kang Zhongyuan Biotechnology Co., Ltd. recalls QC Quality ChoiceThis recall is being initiated following FDA's recommendation based on certain observations noted during an August 15, 2025, inspection of the manufacturing facility that may bear on product quality.
-
Class IIofficial
Xiamen Kang Zhongyuan Biotechnology Co., Ltd. recalls QC Quality ChoiceThis recall is being initiated following FDA's recommendation based on certain observations noted during an August 15, 2025, inspection of the manufacturing facility that may bear on product quality.
-
Class IIofficial
Xiamen Kang Zhongyuan Biotechnology Co., Ltd. recalls QC Quality ChoiceThis recall is being initiated following FDA's recommendation based on certain observations noted during an August 15, 2025, inspection of the manufacturing facility that may bear on product quality.
-
Class IIofficial
Xiamen Kang Zhongyuan Biotechnology Co., Ltd. recalls QC Quality ChoiceThis recall is being initiated following FDA's recommendation based on certain observations noted during an August 15, 2025, inspection of the manufacturing facility that may bear on product quality.
-
Class IIofficial
Xiamen Kang Zhongyuan Biotechnology Co., Ltd. recalls QC Quality ChoiceThis recall is being initiated following FDA's recommendation based on certain observations noted during an August 15, 2025, inspection of the manufacturing facility that may bear on product quality.
-
Class IIofficial
Xiamen Kang Zhongyuan Biotechnology Co., Ltd. recalls QC Quality ChoiceThis recall is being initiated following FDA's recommendation based on certain observations noted during an August 15, 2025, inspection of the manufacturing facility that may bear on product quality.
-
Class IIofficial
Leading Pharma, LLC recalls Furosemide TabletsCGMP Deviations; presence of N-nitroso-Furosemide (NNF) above the recommended intake limit.
-
Class IIofficial
Amneal Pharmaceuticals, LLC recalls traMADol Hydrochloride TabletsFailed Impurities/Degradation Specifications: N-nitroso-desmethyl-tramadol impurity (NDSRI) was found out of the specification at 24-month stability interval during Long term stability (25¿C/60%RH).
-
Class IIofficial
Teva Pharmaceuticals USA, Inc recalls Clonidine Transdermal SystemCGMP Deviations: use of an unapproved raw material
-
Class IIofficial
Teva Pharmaceuticals USA, Inc recalls Clonidine Transdermal SystemCGMP Deviations: use of an unapproved raw material
-
Class IIofficial
Teva Pharmaceuticals USA, Inc recalls Clonidine Transdermal SystemCGMP Deviations: use of an unapproved raw material
-
Class Iofficial
Amneal Pharmaceuticals, LLC recalls Magnesium Sulfate in Water for InjectionProduct mix up: a foil pouch labeled "Magnesium Sulfate in Water for Injection, 4 g/100 mL" actually contained an IV bag of Tranexamic Acid instead.
-
Class IIIofficial
Island Kinetics, Inc. d.b.a. CoValence Laboratories recalls Remedy GelSubpotent Drug
-
Class IIIofficial
Island Kinetics, Inc. d.b.a. CoValence Laboratories recalls Skin RehabSubpotent Drug
-
Class IIIofficial
Island Kinetics, Inc. d.b.a. CoValence Laboratories recalls Essential Calming Skin GelSubpotent Drug
-
Class IIofficial
Chiesi USA, Inc. recalls CUROSURF (poractant alfa)Lack of Assurance of Sterility
-
Class IIofficial
Teva Pharmaceuticals USA, Inc recalls Octreotide Acetate for Injectable SuspensionLack of Assurance of Sterility: Quality system deficiencies identified during a routine U.S Food and Drug Administration (FDA) inspection at the contract manufacturer.
-
Class IIofficial
Teva Pharmaceuticals USA, Inc recalls Octreotide Acetate for Injectable SuspensionLack of Assurance of Sterility: Quality system deficiencies identified during a routine U.S Food and Drug Administration (FDA) inspection at the contract manufacturer.
-
Class IIofficial
Teva Pharmaceuticals USA, Inc recalls Octreotide Acetate for Injectable SuspensionLack of Assurance of Sterility: Quality system deficiencies identified during a routine U.S Food and Drug Administration (FDA) inspection at the contract manufacturer.
-
Class IIofficial
Viatris, Inc. recalls Xanax XRFailed Dissolution Specifications
-
Class IIofficial
Nephron SC, LLC recalls Albuterol Sulfate Inhalation SolutionLabelling: Illegible label
-
Class IIofficial
Amerisource Health Services LLC recalls Meclizine Hydrochloride TabletsFailed tablet specifications.
-
Class IIofficial
Cipla USA, Inc. recalls Cinacalcet Hydrochloride TabletsCGMP Deviations; presence N-Nitroso Cinacalcet above the acceptable daily intake limit
-
Class IIofficial
Cipla USA, Inc. recalls Cinacalcet Hydrochloride TabletsCGMP Deviations; presence N-Nitroso Cinacalcet above the acceptable daily intake limit
-
Class IIofficial
Cipla USA, Inc. recalls Cinacalcet Hydrochloride TabletsCGMP Deviations; presence N-Nitroso Cinacalcet above the acceptable daily intake limit
-
Class IIofficial
Cipla USA, Inc. recalls Lanreotide InjectionLack of Assurance of Sterility: Due to an FDA observation at the contract manufacturing site for deficiencies in their visual inspection procedure.
-
Class IIofficial
Cipla USA, Inc. recalls Lanreotide InjectionLack of Assurance of Sterility: Due to an FDA observation at the contract manufacturing site for deficiencies in their visual inspection procedure.
-
Class IIofficial
ENDO USA, Inc. recalls Buprenorphine HydrochlorideCrystallization; identified as Buprenorphine free base
-
Class IIofficial
Fresenius Kabi USA, LLC recalls 0.45% Sodium Chloride InjectionLack of Assurance of Sterility
-
Class IIofficial
Fresenius Kabi USA, LLC recalls 0.9% Sodium Chloride InjectionLack of Assurance of Sterility
-
Class IIofficial
Fresenius Kabi USA, LLC recalls 0.9% Sodium Chloride InjectionLack of Assurance of Sterility
-
Class IIofficial
Fresenius Kabi USA, LLC recalls 0.9% Sodium Chloride InjectionLack of Assurance of Sterility